Pathogenesis of M.pneumoniae Reactive Airway Disease

肺炎支原体反应性气道疾病的发病机制

基本信息

  • 批准号:
    7012708
  • 负责人:
  • 金额:
    $ 11.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-05-01 至 2008-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The incidence and prevalence of asthma has dramatically increased in the last decades. The CDC estimated that in 1998 asthma affected approximately 17 million people in the United States or 6.4% of the population. Mycoplasma pneumoniae is recognized as a common etiologic agent of acute lower respiratory infection in children and adults. More recently M. pneumoniae has been associated with reactive airway disease and asthma. To study the pathogenesis of M. pneumoniae infection in the respiratory tract and its potential role in asthma, we have established a murine model of acute and chronic M. pneumoniae respiratory infection that manifests airway obstruction, airway hyperreactivity, and pulmonary inflammation. Results from our initial studies, as well as from other investigators, indicate that the production of TH1 and TH2 cytokines in the lower respiratory tract may play an important role in both the acute manifestations and chronic sequelae of M. pneumoniae infection. The central hypothesis of this proposal is that M. pneumoniae lower respiratory tract infection leads to alterations in the pulmonary expression of TH1 and TH2 cytokines and that these cytokines are involved in the development of airway obstruction, increased airway hyperreactivity, and histologic inflammation. We believe that this research may ultimately result in new immunomodulatory strategies to treat children and adults with infection-associated reactive airway disease and asthma. The immediate career goal of the candidate is to procure further training in basic science investigation that will enhance his research skills and allow him to become an independent investigator. As a career focus, the candidate intends to concentrate on the immunopathogenesis of the host microbial pathogen relationship. To achieve this goal, the research proposal calls for the attainment of new scientific technical and intellectual skills while concurrently investigating a timely research topic. The University of Texas Southwestern Medical Center provides a fertile environment both in terms of laboratory assets and experienced, committed faculty necessary for this research and the candidate's career development. This award will facilitate and ensure the eventual transition of the candidate into an independent, academic physician-scientist.
描述(由申请人提供):哮喘的发病率和流行率在过去几十年里急剧增加。美国疾病控制与预防中心估计,1998年,美国约有1700万人患有哮喘,占总人口的6.4%。肺炎支原体是儿童和成人急性下呼吸道感染的常见病原体。最近,肺炎支原体与反应性呼吸道疾病和哮喘有关。为了研究肺炎支原体呼吸道感染的发病机制及其在哮喘中的潜在作用,我们建立了以呼吸道阻塞、气道高反应性和肺部炎症为主要表现的急性和慢性肺炎支原体呼吸道感染的小鼠模型。我们的初步研究结果以及其他研究人员的结果表明,下呼吸道TH1和TH2细胞因子的产生可能在肺炎支原体感染的急性表现和慢性后遗症中发挥重要作用。这一建议的中心假设是肺炎支原体下呼吸道感染导致肺组织TH1和TH2细胞因子表达的改变,这些细胞因子参与了气道阻塞、气道高反应性增加和组织炎症的发展。我们相信,这项研究可能最终导致新的免疫调节策略,以治疗感染相关的反应性呼吸道疾病和哮喘的儿童和成人。 应聘者目前的职业目标是获得基础科学调查方面的进一步培训,这将提高他的研究技能,使他能够成为一名独立的调查人员。作为职业重点,应聘者打算专注于宿主微生物病原体关系的免疫病理机制。为了实现这一目标,研究提案要求获得新的科学技术和智力技能,同时调查一个及时的研究课题。德克萨斯大学西南医学中心提供了一个肥沃的环境,包括实验室资产和经验丰富、敬业的教师,这是这项研究和候选人职业发展所必需的。这一奖项将促进并确保候选人最终转变为一名独立的、学术的内科科学家。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT DOUG HARDY其他文献

ROBERT DOUG HARDY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT DOUG HARDY', 18)}}的其他基金

Novel Mycoplasma pneumoniae Toxin as Mediator of Airway Dysfunction in Mice
新型肺炎支原体毒素作为小鼠气道功能障碍的介质
  • 批准号:
    7686467
  • 财政年份:
    2008
  • 资助金额:
    $ 11.88万
  • 项目类别:
Novel Mycoplasma pneumoniae CARDS Toxin as Mediator of Airway Dysfuntion in Mice
新型肺炎支原体卡毒素作为小鼠气道功能障碍的介质
  • 批准号:
    7150756
  • 财政年份:
    2006
  • 资助金额:
    $ 11.88万
  • 项目类别:
Pathogenesis of M.pneumoniae Reactive Airway Disease
肺炎支原体反应性气道疾病的发病机制
  • 批准号:
    6612598
  • 财政年份:
    2003
  • 资助金额:
    $ 11.88万
  • 项目类别:
Pathogenesis of M.pneumoniae Reactive Airway Disease
肺炎支原体反应性气道疾病的发病机制
  • 批准号:
    6730559
  • 财政年份:
    2003
  • 资助金额:
    $ 11.88万
  • 项目类别:
Pathogenesis of M.pneumoniae Reactive Airway Disease
肺炎支原体反应性气道疾病的发病机制
  • 批准号:
    6846095
  • 财政年份:
    2003
  • 资助金额:
    $ 11.88万
  • 项目类别:
Pathogenesis of M.pneumoniae Reactive Airway Disease
肺炎支原体反应性气道疾病的发病机制
  • 批准号:
    7178454
  • 财政年份:
    2003
  • 资助金额:
    $ 11.88万
  • 项目类别:
Novel Mycoplasma pneumoniae CARDS Toxin as Mediator of Airway Dysfuntion in Mice
新型肺炎支原体卡毒素作为小鼠气道功能障碍的介质
  • 批准号:
    7557459
  • 财政年份:
  • 资助金额:
    $ 11.88万
  • 项目类别:
Novel Mycoplasma pneumoniae Toxin as Mediator of Airway Dysfunction in Mice
新型肺炎支原体毒素作为小鼠气道功能障碍的介质
  • 批准号:
    7904185
  • 财政年份:
  • 资助金额:
    $ 11.88万
  • 项目类别:
Novel Mycoplasma pneumoniae Toxin as Mediator of Airway Dysfunction in Mice
新型肺炎支原体毒素作为小鼠气道功能障碍的介质
  • 批准号:
    8126241
  • 财政年份:
  • 资助金额:
    $ 11.88万
  • 项目类别:

相似国自然基金

大鱼际掌纹特应征与5个哮喘易感基因单核苷酸多态性的关联分析
  • 批准号:
    30873315
  • 批准年份:
    2008
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目
调节性T细胞和共刺激分子在过敏原早期暴露诱导哮喘免疫耐受中的作用机制研究
  • 批准号:
    30740048
  • 批准年份:
    2007
  • 资助金额:
    10.0 万元
  • 项目类别:
    专项基金项目
CBP介导STAT4/STAT6相互拮抗在哮喘Th失衡中的机制
  • 批准号:
    30672268
  • 批准年份:
    2006
  • 资助金额:
    28.0 万元
  • 项目类别:
    面上项目

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 11.88万
  • 项目类别:
    Studentship
Creating healthier homes for children with asthma:Developing a predictive model for environmental
为哮喘儿童创建更健康的家庭:开发环境预测模型
  • 批准号:
    2908612
  • 财政年份:
    2024
  • 资助金额:
    $ 11.88万
  • 项目类别:
    Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
    Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
    Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
  • 批准号:
    10659658
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
Innate immune regulation of lung inflammation through mitochondrial dynamics
通过线粒体动力学调节肺部炎症的先天免疫
  • 批准号:
    10659953
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
NHERF1 regulates MRGPRX2/MrgprB2 responses in mast cells
NHERF1 调节肥大细胞中的 MRGPRX2/MrgprB2 反应
  • 批准号:
    10711042
  • 财政年份:
    2023
  • 资助金额:
    $ 11.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了